Patents by Inventor David Ronald Garrod

David Ronald Garrod has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyruvamide compounds as inhibitors of dust mite group 1 peptidase allergen and their use
    Patent number: 8637453
    Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain pyruvamide compounds of the following formula (for convenience, collectively referred to herein as “PVA compounds”), which, inter alia, inhibit a dust mite Group 1 peptidase allergen (e.g., Der p 1, Der f 1, Eur m 1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit a dust mite Group 1 peptidase allergen, and in the treatment of diseases and disorders that are mediated by a dust mite Group 1 peptidase allergen; that are ameliorated by the inhibition of a dust mite Group 1 peptidase allergen; asthma; rhinitis; allergic conjunctivitis; atopic dermatitis; an allergic condition which is triggered by dust mites; an allergic condition which is triggered by a dust mite Group 1 peptidase allergen; and canine atopy.
    Type: Grant
    Filed: March 28, 2013
    Date of Patent: January 28, 2014
    Assignees: St George's Hospital Medical School, The University of Manchester
    Inventors: Clive Robinson, Jihui Zhang, David Ronald Garrod, Trevor Robert Perrior, Gary Karl Newton, Kerry Jenkins, Rebekah Elisabeth Key, Meriel Ruth Major, Mark Richard Stewart
  • Pyruvamide compounds as inhibitors of dust mite group 1 peptidase allergen and their use
    Patent number: 8541363
    Abstract: The present invention pertains generally to the field of therapeutic compounds and more specifically to certain pyruvamide compounds of the formula (X) (for convenience, collectively referred to herein as “PVA compounds”), which, inter alia, inhibit a dust mite Group 1 peptidase allergen (e.g., Der p 1, Der f 1, Eur m 1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit a dust mite Group 1 peptidase allergen, and in the treatment of diseases and disorders that are mediated by a dust mite Group 1 peptidase allergen; that are ameliorated by the inhibition of a dust mite Group 1 peptidase allergen; asthma; rhinitis; allergic conjunctivitis; atopic dermatitis; an allergic condition which is triggered by dust mites; an allergic condition which is triggered by a dust mite Group 1 peptidase allergen; and canine atopy.
    Type: Grant
    Filed: January 21, 2011
    Date of Patent: September 24, 2013
    Assignees: St George's Hosptial Medical School, The University of Manchester
    Inventors: Clive Robinson, Jihui Zhang, David Ronald Garrod, Trevor Robert Perrior, Gary Karl Newton, Kerry Jenkins, Rebekah Elisabeth Beevers, Meriel Ruth Major, Mark Richard Stewart
  • Pyruvamide Compounds as Inhibitors of Dust Mite Group 1 Peptidase Allergen and Their Use
    Publication number: 20130217617
    Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain pyruvamide compounds of the following formula (for convenience, collectively referred to herein as “PVA compounds”), which, inter alia, inhibit a dust mite Group 1 peptidase allergen (e.g., Der p 1, Der f 1, Eur m 1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit a dust mite Group 1 peptidase allergen, and in the treatment of diseases and disorders that are mediated by a dust mite Group 1 peptidase allergen; that are ameliorated by the inhibition of a dust mite Group 1 peptidase allergen; asthma; rhinitis; allergic conjunctivitis; atopic dermatitis; an allergic condition which is triggered by dust mites; an allergic condition which is triggered by a dust mite Group 1 peptidase allergen; and canine atopy.
    Type: Application
    Filed: March 28, 2013
    Publication date: August 22, 2013
    Applicants: The University of Manchester, St George's Hospital Medical School
    Inventors: Clive Robinson, Jihui Zhang, David Ronald Garrod, Trevor Robert Perrior, Gary Karl Newton, Kerry Jenkins, Rebekah Elisabeth Key, Meriel Ruth Major, Mark Richard Stewart
  • Pyruvamide Compounds as Inhibitors of Dust Mite Group 1 Peptidase Allergen and Their Use
    Publication number: 20120322722
    Abstract: The present invention pertains generally to the field of therapeutic compounds and more specifically to certain pyruvamide compounds of the formula (X) (for convenience, collectively referred to herein as “PVA compounds”), which, inter alia, inhibit a dust mite Group 1 peptidase allergen (e.g., Der p 1, Der f 1, Eur m 1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit a dust mite Group 1 peptidase allergen, and in the treatment of diseases and disorders that are mediated by a dust mite Group 1 peptidase allergen; that are ameliorated by the inhibition of a dust mite Group 1 peptidase allergen; asthma; rhinitis; allergic conjunctivitis; atopic dermatitis; an allergic condition which is triggered by dust mites; an allergic condition which is triggered by a dust mite Group 1 peptidase allergen; and canine atopy.
    Type: Application
    Filed: January 21, 2011
    Publication date: December 20, 2012
    Applicants: THE UNIVERSITY OF MANCHESTER, ST GEORGE'S HOSPITAL MEDICAL SCHOOL
    Inventors: Clive Robinson, Jihui Zhang, David Ronald Garrod, Trevor Robert Perrior, Gary Karl Newton, Kerry Jenkins, Rebekah Elisabeth Beevers, Meriel Ruth Major, Mark Richard Stewart